$\begin{array}{c} \rm J1 \\ \rm CF~SB~557 \end{array}$

By: Delegate Adams

Introduced and read first time: February 6, 2019 Assigned to: Health and Government Operations

A BILL ENTITLED

1 AN ACT concerning

Public Health - Tick-Borne Disease Interagency Workgroup

3 FOR the purpose of establishing the Tick-Borne Disease Interagency Workgroup; 4 providing for the composition, chair, and staffing of the Workgroup; requiring the 5 Workgroup to hold certain meetings; prohibiting a member of the Workgroup from 6 receiving certain compensation, but authorizing the reimbursement of certain 7 expenses; requiring the Workgroup to solicit input from certain stakeholders and 8 study and make recommendations regarding certain matters; requiring the 9 Workgroup to submit an interim and a final report to certain committees of the General Assembly on or before certain dates; providing for the termination of this 10 11 Act; and generally relating to the Tick-Borne Disease Interagency Workgroup.

12 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,

13 That:

14

20

2

- (a) There is a Tick–Borne Disease Interagency Workgroup.
- 15 (b) The Workgroup consists of the following members:
- 16 (1) one member of the Senate of Maryland, appointed by the President of 17 the Senate:
- 18 (2) one member of the House of Delegates, appointed by the Speaker of the
- 19 House;
- (3) the Secretary of Health, or the Secretary's designee;
- 21 (4) the Secretary of Agriculture, or the Secretary's designee;
- 22 (5) the Secretary of the Environment, or the Secretary's designee;

(1)

review:

29

HOUSE BILL 660

1		(6)	the Secretary of Natural Resources, or the Secretary's designee;
2 3	Center;	(7)	one representative of the University of Maryland Agricultural Research
4 5	Council;	(8)	one representative of the University of Maryland Global Leadership
6		(9)	seven members, appointed by the Secretary of Health, representing:
7 8	tick-borne d	lisease	(i) health care providers with experience diagnosing and treating es;
9			(ii) scientists or researchers with expertise in tick-borne diseases;
0			(iii) patients with tick-borne diseases and their family members; and
$\frac{1}{2}$	tick-borne d	lisease	(iv) nonprofit organizations that advocate for patients with es; and
13 14 15			representatives of other State agencies, the Johns Hopkins School of e University of Maryland Medical System, and the Maryland Hospital termined by the Secretary of Health.
16 17	(c) section shall		members of the Workgroup described in subsection (b)(9) and (10) of this esent a diversity of scientific disciplines and views.
18	(d)	The S	Secretary of Health shall designate the chair of the Workgroup.
9	(e)	The N	Maryland Department of Health shall provide staff for the Workgroup.
20	(f)	The V	Workgroup shall meet at least twice annually.
21	(g)	A me	mber of the Workgroup:
22		(1)	may not receive compensation as a member of the Workgroup; but
23 24	Travel Regu	(2) ılation	is entitled to reimbursement for expenses under the Standard States, as provided in the State budget.
25 26 27		vities o	ourpose of the Workgroup is to provide subject matter expertise and to of federal and State agencies related to tick—borne diseases to ensure nation, minimize overlap, and examine research priorities.
28	(i)	The V	Workgroup shall:

1 2 3	(i) ongoing tick-borne disease research, including research related to causes, prevention, treatment, surveillance, diagnosis, duration of illness, and intervention for individuals with tick-borne diseases; and
4 5	(ii) federal and State activities related to tick-borne diseases, including:
6	1. epidemiological activities;
7 8 9	2. basic, clinical, and translational tick-borne disease research related to the pathogenesis, prevention, diagnosis, and treatment of tick-borne diseases; and
10 11 12	3. actions undertaken by federal agencies and researchers, including the federal Department of Health and Human Services and the National Institutes of Health;
13 14 15 16	(2) solicit input from stakeholders, including organizations representing patients, health care providers, researchers, and industry, regarding scientific advances, research questions, surveillance activities, and emerging strains in species of pathogenic organisms;
17	(3) develop a summary of:
18 19 20	(i) the research, activities, and actions reviewed under item (1) of this subsection, including advances made as a result of the research, and gaps in the research;
21	(ii) the Workgroup's meetings; and
22	(iii) public comments received by the Workgroup; and
23 24 25	(4) make recommendations regarding any appropriate changes, including improvements, that should be made regarding research and activities regarding tick—borne diseases.
26 27 28 29	(j) (1) On or before December 1, 2019, the Workgroup shall submit an interim report of its findings and recommendations to the Senate Education, Health, and Environmental Affairs Committee and the House Health and Government Operations Committee in accordance with § 2–1246 of the State Government Article.
30 31 32	(2) On or before December 1, 2020, the Workgroup shall submit a final report of its findings and recommendations to the Senate Education, Health, and Environmental Affairs Committee and the House Health and Government Operations

Committee in accordance with § 2-1246 of the State Government Article.

33

SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect July 1, 2019. It shall remain effective for a period of 2 years and, at the end of June 30, 2021, this Act, with no further action required by the General Assembly, shall be abrogated and of no further force and effect.